547-P: Associations between Bladder Symptoms and Diabetic Neuropathy in a Romanian Cohort of Patients with Diabetes

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 547-P
Author(s):  
CAMELIA L. VONICA ◽  
COSMINA I. BONDOR ◽  
DIANA SIMA ◽  
DANIEL T. COSMA ◽  
IOAN ANDREI VERESIU ◽  
...  
2021 ◽  
Vol 14 ◽  
Author(s):  
Mayur Bhimrao Kale ◽  
Komal Bajaj ◽  
Mohit Umare ◽  
Nitu L. Wankhede ◽  
Brijesh Gulabrao Taksande ◽  
...  

: Diabetic neuropathy is an incapacitating chronic pathological condition that encompasses a large group of diseases and manifestations of nerve damage. It affects approximately 50% of patients with diabetes mellitus. Autonomic, sensory, and motor neurons are affected. Disabilities are severe, along with poor recovery and diverse pathophysiology. Physical exercise and herbal-based therapies have the potential to decrease the disabilities associated with diabetic neuropathy. Aerobic exercises like walking, weight lifting, the use of nutraceuticals and herbal extracts are found to be effective. Literature from the public domain was studied emphasizing various beneficial effects of different exercises, use of herbal and nutraceuticals for their therapeutic action in diabetic neuropathy. Routine exercises and administration of herbal and nutraceuticals, either the extract of plant material containing the active phytoconstituent or isolated phytoconstituent at safe concentration, have been shown to have promising positive action in the treatment of diabetic neuropathy. Exercise has shown promising effects on vascular and neuronal health and has proven to be well effective in the treatment as well as prevention of diabetic neuropathy by various novel mechanisms, including herbal and nutraceuticals therapy is also beneficial for the condition. They primarily show the anti-oxidant effect, secretagogue, anti-inflammatory, analgesic, and neuroprotective action. Severe adverse events are rare with these therapies. The current review investigates the benefits of exercise and nutraceutical therapies in the treatment of diabetic neuropathy.


2011 ◽  
Vol 22 ◽  
pp. S29
Author(s):  
Triada Exiara ◽  
Apostolos Konstantis ◽  
Maria Kouroupi ◽  
Anastasia Georgoulidou ◽  
Dimitra Papadopoulou ◽  
...  

Diabetes Care ◽  
2018 ◽  
Vol 41 (10) ◽  
pp. e139-e140
Author(s):  
Anca Jivanescu ◽  
Cosmina I. Bondor ◽  
Rodica Pop-Busui ◽  
Ioan A. Veresiu ◽  
Diana I. Sima ◽  
...  

2021 ◽  
Vol 12 (Vol.12, no.1) ◽  
pp. 61-64
Author(s):  
Dan TROFIN ◽  
Daniela MATEI ◽  
Teodor STAMATE ◽  
Bild WALTHER ◽  
TROFIN Daniela Marilena

Abstract Diabetic Neuropathy (DN) is a complication that affects at least half of the patients with Diabetes Mellitus. Unlike other symptoms and signs that may sooner alarm the patients, DN manifestations tend to be rather silent, and so usually neglected by the patient for a long period of time, which can last for years. Therefore it’s a “hidden complication of diabetes” label. Unfortunately, it is only when symptoms already affect the quality of life that the treatment becomes challenging when it comes to speaking of either etiological, symptomatic or rehabilitation strategies. Early diagnosis can also be tricky while aiming for lifestyle corrections and proper individualized treatment strategies. Rehabilitation methods for DN aim especially towards the improvement of articulation mobility and muscular strength amelioration, the suggested brief review of literature promoting this part of therapy essential for both prevention and amelioration of overall morbidity. Keywords: diabetic neuropathy, physical therapy, interdisciplinary approach, quality of life,


2021 ◽  
Vol 2021 ◽  
pp. 1-20
Author(s):  
Md. Tanvir Kabir ◽  
Nuzhat Tabassum ◽  
Md. Sahab Uddin ◽  
Faissal Aziz ◽  
Tapan Behl ◽  
...  

Diabetic neuropathy (DN) is a common and serious diabetes-associated complication that primarily takes place because of neuronal dysfunction in patients with diabetes. Use of current therapeutic agents in DN treatment is quite challenging because of their severe adverse effects. Therefore, there is an increased need of identifying new safe and effective therapeutic agents. DN complications are associated with poor glycemic control and metabolic imbalances, primarily oxidative stress (OS) and inflammation. Various mediators and signaling pathways such as glutamate pathway, activation of channels, trophic factors, inflammation, OS, advanced glycation end products, and polyol pathway have a significant contribution to the progression and pathogenesis of DN. It has been indicated that polyphenols have the potential to affect DN pathogenesis and could be used as potential alternative therapy. Several polyphenols including kolaviron, resveratrol, naringenin, quercetin, kaempferol, and curcumin have been administered in patients with DN. Furthermore, chlorogenic acid can provide protection against glutamate neurotoxicity via its hydrolysate, caffeoyl acid group, and caffeic acid through regulating the entry of calcium into neurons. Epigallocatechin-3-gallate treatment can protect motor neurons by regulating the glutamate level. It has been demonstrated that these polyphenols can be promising in combating DN-associated damaging pathways. In this article, we have summarized DN-associated metabolic pathways and clinical manifestations. Finally, we have also focused on the roles of polyphenols in the treatment of DN.


2020 ◽  
Vol 8 (1) ◽  
pp. e001566
Author(s):  
Eva Sierra-Silvestre ◽  
Mari Somerville ◽  
Leanne Bisset ◽  
Michel W Coppieters

The first signs of diabetic neuropathy typically result from small-diameter nerve fiber dysfunction. This review synthesized the evidence for small-diameter nerve fiber neuropathy measured via quantitative sensory testing (QST) in patients with diabetes with and without painful and non-painful neuropathies. Electronic databases were searched to identify studies in patients with diabetes with at least one QST measure reflecting small-diameter nerve fiber function (thermal or electrical pain detection threshold, contact heat-evoked potentials, temporal summation or conditioned pain modulation). Four groups were compared: patients with diabetes (1) without neuropathy, (2) with non-painful diabetic neuropathy, (3) with painful diabetic neuropathy and (4) healthy individuals. Recommended methods were used for article identification, selection, risk of bias assessment, data extraction and analysis. For the meta-analyses, data were pooled using random-effect models. Twenty-seven studies with 2422 participants met selection criteria; 18 studies were included in the meta-analysis. Patients with diabetes without symptoms of neuropathy already showed loss of nerve function for heat (standardized mean difference (SMD): 0.52, p<0.001), cold (SMD: −0.71, p=0.01) and electrical pain thresholds (SMD: 1.26, p=0.01). Patients with non-painful neuropathy had greater loss of function in heat pain threshold (SMD: 0.75, p=0.01) and electrical stimuli (SMD: 0.55, p=0.03) compared with patients with diabetes without neuropathy. Patients with painful diabetic neuropathy exhibited a greater loss of function in heat pain threshold (SMD: 0.55, p=0.005) compared with patients with non-painful diabetic neuropathy. Small-diameter nerve fiber function deteriorates progressively in patients with diabetes. Because the dysfunction is already present before symptoms occur, early detection is possible, which may assist in prevention and effective management of diabetic neuropathy.


2019 ◽  
Vol 317 (2) ◽  
pp. F388-F398 ◽  
Author(s):  
Nicole S. Klee ◽  
Robert S. Moreland ◽  
Derek M. Kendig

Diabetic bladder dysfunction (DBD) affects up to 50% of all patients with diabetes, characterized by symptoms of both overactive and underactive bladder. Although most diabetic bladder dysfunction studies have been performed using models with type 1 diabetes, few have been performed in models of type 2 diabetes, which accounts for ~90% of all diabetic cases. In a type 2 rat model using a high-fat diet (HFD) and two low doses of streptozotocin (STZ), we examined voiding measurements and functional experiments in urothelium-denuded bladder strips to establish a timeline of disease progression. We hypothesized that overactive bladder symptoms (compensated state) would develop and progress into symptoms characterized by underactive bladder (decompensated state). Our results indicated that this model developed the compensated state at 1 wk after STZ and the decompensated state at 4 mo after STZ administration. Diabetic bladders were hypertrophied compared with control bladders. Increased volume per void and detrusor muscle contractility to exogenous addition of carbachol and ATP confirmed the development of the compensated state. This enhanced contractility to carbachol was not due to increased levels of M3 receptor expression. Decompensation was characterized by increased volume per void, number of voids, and contractility to ATP but not carbachol. Thus, progression from the compensated to decompensated state may involve decreased contractility to muscarinic stimulation. These data suggest that the compensated state of DBD progresses temporally into the decompensated state in the male HFD/STZ model of diabetes; therefore, this male HFD/STZ model can be used to study the progression of DBD.


2020 ◽  
pp. 49-52
Author(s):  
Padma Kumar G ◽  
Selvan P ◽  
George Zachariah ◽  
S Abdul Gafoor

BACKGROUND Diabetes Mellitus is a major health problem of which Diabetic Peripheral Neuropathy (DPN) is an important complication resulting in ulceration and amputation. There are a number of bedside tests and evaluation which has been suggested for early diagnosis of DPN. This study aims to evaluate the usefulness of Biothesiometry when combined along with Diabetic Neuropathy Symptom Score (DNS) and Diabetic Neuropathy Examination Score (DNE) as compared against Nerve Conduction Study (NCS). NCS is considered as the gold standard in diagnosis of DPN. METHODS This is a cross-sectional study which was done in the Department of Physical Medicine & Rehabilitation, Government Medical College, Thiruvananthapuram, Kerala which is a tertiary level referral center. The study was done in a one-year period between January 2018 and January 2019 in patients with diabetes who satisfied the inclusion criteria. Patients were first evaluated with a Performa which included DNS and DNE scoring and compared with NCS parameters. Vibration Perception Threshold (VPT) was assessed with a Biothesiometer and the combined results were compared with Nerve Conduction Study (NCS). The values obtained were entered in excel sheet and statistically evaluated. RESULTS 127 patients with Diabetes were recruited into the study out of which 49 were males and 78 were females with a mean age of 57.2 +/- 9.9 years. When patients who were clinically positive for DPN on evaluation with DNS and DNE were compared with NCS parameters, it was shown that there was a sensitivity of 96.2 % and specificity of 38.1% and when VPT measurement using Biothesiometer was added to the clinical evaluation the sensitivity was 100% with a negative predictive value of 100% and specificity of 23.8%. This study has shown that all of the patients who tested negative were true negatives. CONCLUSION This study concluded that addition of Biothesiometry to the combination of DNS, DNE for the evaluation of DPN is as good as NCS evaluation. Hence this combination will be useful in rural settings, where accessibility to expensive Electrodiagnostic machine is limited.


Sign in / Sign up

Export Citation Format

Share Document